Research Article

The Level of Serum Albumin Is Associated with Renal Prognosis in Patients with Diabetic Nephropathy

Junlin Zhang, Rui Zhang, Yiting Wang, Hanyu Li, Qianqian Han, Yucheng Wu, Tingli Wang, and Fang Liu

Division of Nephrology, West China Hospital of Sichuan University, Chengdu 610041, China

Correspondence should be addressed to Fang Liu; liufangfh@163.com

Received 10 August 2018; Revised 2 December 2018; Accepted 23 December 2018; Published 17 February 2019

Academic Editor: Raffaella Mastrocola

Copyright © 2019 Junlin Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Although hypoalbuminemia is frequently found in most patients with diabetic nephropathy (DN), its relationship to the severity and progression of DN remains largely unknown. Our aim was to investigate the association between the serum albumin levels and clinicopathological features and renal outcomes in patients with type 2 diabetes mellitus (T2DM) and biopsy-proven DN.

Materials and Methods. A total of 188 patients with T2DM and biopsy-proven DN followed up for at least one year were enrolled. The patients were divided into four groups based on the albumin levels: normal group: ≥35 g/L (n = 87); mild group: 30-35 g/L (n = 34); moderate group: 25-30 g/L (n = 36); and severe group: <25 g/L (n = 31). The renal outcome was defined by progression to end-stage renal disease. The impact of the serum albumin level on renal survival was estimated using Cox regression analysis.

Results. Among the cases, the serum albumin level had a significant correlation with proteinuria, renal function, and glomerular lesions. A multivariate Cox regression analysis indicated that the severity of hypoalbuminemia remained significantly associated with an adverse renal outcome, independent of clinical and histopathological features. In reference to the normal group, the risk of progression to ESRD increased such that the hazard ratio (HR) for the mild group was 2.09 (95% CI, 0.67-6.56, p = 0.205), 6.20 (95% CI, 1.95-19.76, p = 0.002) for the moderate group, and 7.37 (95% CI, 1.24-43.83, p = 0.028) for the severe group.

Conclusions. These findings suggested that hypoalbuminemia was associated with a poorer renal prognosis in patients with T2DM and DN.

1. Introduction

Diabetic nephropathy (DN), recently also named as diabetic kidney disease (DKD), is one of the most common diabetic microvascular complications and has become the leading cause of chronic kidney diseases in the world [1, 2]. DN develops in approximately 40% of type 2 diabetic (T2D) patients [3] and nearly 20% of whom will finally progress to end-stage renal disease (ESRD) [4]. The previous surveys reported that DN accounted for roughly 16.4% [5] and more than 44% [6] of all cases of ESRD in China and in the USA, respectively. Although the renoprotective interventions have been universally implemented to improve glycemia, blood pressure, and serum lipid regulation over the last decades, the risk of ESRD and the health burden in DN patients is still increasing [7]. Searching further insight into the pathogenesis and risk factors for DN development is extremely urgent and essential to advance clinical management of DN.

DN is greatly a heterogeneous kidney disease, with variability in clinical courses, histopathological features, and different disease trajectories. The clinical characteristics of DN have traditionally been described as glomerular hyperfiltration, persistent albuminuria, hypertension, and finally progression to renal failure. And the typical histomorphology of DN displays glomerular basement membrane (GBM) thickening, mesangial matrix expansion, nodule sclerosis, and diffuse podocyte foot process effacement [3]. Although a large body of studies has established the contribution of several factors such as severity of glomerular lesions and proteinuria in the progression of DN [8–11], the number of researches about the association between the serum albumin and biopsy-proven DN was very limited.
In this study, we aimed to investigate the relationship between serum albumin levels and the baseline clinicopathological features in 188 patients with T2DM and biopsy-proven DN and to further evaluate the prognostic utility of serum albumin levels.

2. Materials and Methods

2.1. Ethical Approval. The ethics committee of West China Hospital approved this research. The study protocol was in compliance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.

2.2. Patients. A total of 291 patients with T2DM and biopsy-proven DN in West China Hospital of Sichuan University from 2008 to 2016 were reviewed, and 188 patients were eligible (Figure 1). The general indications for renal biopsy in our present study were T2DM patients with renal damage who lacked absolute contraindications, especially T2DM patients without diabetic retinopathy (DR), T2DM patients with obvious glomerular hematuria and/or sudden onset of overt proteinuria, or T2DM patients with short diabetic duration (<5 y). The diagnosis of T2DM and DN was in accordance with the standards which were established by the American Diabetes Association (ADA) in 2017 [12] and the Renal Pathology Society in 2010 [13], respectively. Exclusion criteria were the patients that coexisted with non-diabetic renal diseases (NDRDs) such as IgA nephropathy or systemic diseases, especially cancer and cirrhosis. The patients who were followed up less than 1 year, without information of the serum albumin level, or having progressed to ESRD before renal biopsy were also excluded.

2.3. Clinical and Pathologic Characteristics. The clinical data, including the age, gender, weight, height, history of diabetes, blood pressure, HbA1c, 24 h urinary protein, serum creatinine (mg/dL), estimated glomerular filtration rate (e-GFR), evaluated by the CKD-EPI formula), serum albumin, total cholesterol, triglyceride, and hemoglobin, were gathered at the time of renal biopsy. The information of the medication history, especially the antidiabetic agents and RAAS (renin-angiotensin-aldosterone system) inhibitor including angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), were also collected at baseline. The level of serum albumin was measured by the bromocresol green (BCG). Hypoalbuminemia was defined as a serum albumin level < 35 g/L, and clinically significant hypoalbuminemia was generally regarded as a level < 25 g/L [14]. Given that, the patients in this study were divided into 4 groups according to the level of serum albumin: normal albumin group (≥35 g/L), mild hypoalbuminemia group (30-35 g/L), moderate hypoalbuminemia group (25-30 g/L), and severe hypoalbuminemia group (<25 g/L). All renal biopsy specimens of this study were routinely examined by light microscopy, immunofluorescence, and electron microscopy. The histological lesions were graded according to the new criteria of the Renal Pathology Society in 2010 [13].

2.4. Follow-Up and Renal Outcome. The patients were followed up regularly and the information about their proteinuria and renal function was collected. The renal outcome in this study was defined by progression to ESRD, which was regarded as e – GFR < 15 mL/min/1.73 m² or starting the renal replacing therapy.

2.5. Statistical Analysis. All statistical tests were analyzed by SPSS version 22.0 for Windows Inc. (Chicago, IL, USA). The continuous variables were presented as the mean ± standard deviation (SD) or median with IQR, and categorical data were summarized as numbers and percentages. Differences in means for quantitative variables were evaluated using ANOVA or the Kruskal–Wallis H test, as appropriate. Categorical variables were compared with the chi-squared test. Correlations of the serum albumin level with histopathological findings were analyzed by Spearman’s correlation analysis and with the clinical findings by partial correlation adjusting for the baseline age, gender, and e-GFR. Cumulative survival was presented as Kaplan–Meier survival curves, and survival rates were assessed using the log-rank test. Cox regression models were performed to analyze the association between the levels of albumin and renal outcomes. The serum albumin level was first calculated as a continuous variable with hazard ratios (HRs) that resulted from each SD increment, and the different albumin level groups as a categorical variable, with the normal group regarded as reference. The factors that had clinical meaning or were associated with renal outcomes in univariate analysis (p < 0.1) were included in the multivariate Cox regression analysis. The area under the receiver operating characteristic curve (AUC) and integrated discrimination improvement (IDI) were analyzed by using logistic regression to identify the discrimination ability [15]. A two-sided p value <0.05 was considered statistically significant, and the Holm–Bonferroni method was applied to reduce the risk of a type 1 statistical error.

3. Results

3.1. Baseline Clinical and Pathologic Characteristics. A total of 188 patients were recruited in this study, and there is no significant difference observed between the included and excluded participants on the demographic and clinical characteristics, except for the e-GFR (Supplementary Table 1). There were 87 (46.3%) patients in the normal group, 34 (18.1%) in the mild group, 36 (19.1%) in the moderate group, and 31 (16.5%) in the severe group. At the time of renal biopsy, 129 patients were male (68.6%) and the mean age was 52.71 ± 8.79 years old. The median follow-up time was 17 (IQR, 12-103) months. The median duration of diabetes was 90 (36-132) months. The median of the serum creatinine level was 1.42 (1.02-1.82) mg/dL, the median of the e-GFR was 51.25 (37.44-77.91) mL/min/1.73 m², the median of the albumin level was 34.15 (27.28-39.38) g/L, and the median of proteinuria was...
4.09 (1.88-6.75) g/day at baseline. 152 (80.9%) patients received the RAAS inhibitor therapy prior to the admission. 76 patients (40.4%) progressed to ESRD from baseline during the follow-up period. The distribution by glomerular classes I, IIa, IIb, III, and IV was 5.3% (10), 18.1% (34), 10.6% (20), 50.5% (95), and 15.4% (29), respectively. The severe glomerular lesions (class III+IV) of the normal, mild, moderate, and severe groups were observed in 40 (46.0%), 27 (79.4%), 30 (83.3%), and 27 (87.1%), respectively. Clinical and pathological features of patients with different serum albumin levels are presented in Table 1.

3.2. Associations between the Albumin Level and the Clinicopathological Features. Among patients, we observed no significant relationship of albumin levels with the age, gender, duration of diabetes, glycosylated hemoglobin levels, and incidence of smoking and hypertension (Table 1). There was a significant trend for higher creatinine, proteinuria, and cholesterol and lower e-GFR and hemoglobin in the moderate and severe groups than in the other groups. There was no difference in the use of RAAS inhibitors among groups.

The correlations between the albumin levels and clinicopathological findings are illustrated in Table 2. The albumin level showed a significant inverse correlation with the glomerular class \( (r = -0.394, p < 0.001) \), as well as a weak negative relationship with the IFTA score \( (r = -0.269, p < 0.001) \), interstitial inflammation score \( (r = -0.378, p < 0.001) \), and arteriolar hyalinosis score \( (r = -0.219, p = 0.003) \). Moreover, the albumin level had a strong inverse correlation with proteinuria \( (r = -0.661, p < 0.001) \) and cholesterol \( (r = -0.424, p < 0.001) \) and a positive correlation with e-GFR \( (r = 0.334, p < 0.001) \) or hemoglobin \( (r = 0.325, p < 0.001) \) when adjusting for the baseline age, gender, and e-GFR.

3.3. Serum Albumin Level and Renal Outcome. The Kaplan–Meier survival analysis suggested an overall 5-year renal survival rate of 29.0% in all the patients. Patients of different albumin levels had 5-year renal survival rates of 64.14% (normal group), 35.70% (mild group), 10.54% (moderate group), and 0% (severe group). Median survival time for ESRD after renal biopsy was 31 months, 24 months, and
Table 1: Baseline clinical and pathological findings in groups stratified according to the serum albumin level.

| Variables                              | Normal group ≥ 35 g/L (\(n = 87\)) | Mild group 30-35 g/L (\(n = 34\)) | Moderate group 25-30 g/L (\(n = 36\)) | Severe group < 25 g/L (\(n = 31\)) | \(p\) value |
|----------------------------------------|-------------------------------------|------------------------------------|--------------------------------------|----------------------------------|-------------|
| **Clinical findings**                  |                                     |                                    |                                      |                                  |             |
| Age (year)                             | 52.45 ± 9.66                        | 53.41 ± 8.93                       | 53.06 ± 6.32                        | 52.26 ± 8.88                    | 0.935       |
| Gender (male)                          | 60 (69.0%)                          | 25 (73.5%)                         | 22 (61.1%)                          | 22 (71.0%)                      | 0.704       |
| Duration of diabetes (months)          | 84 (24-132)                         | 48 (24-120)                        | 120 (36-156)                        | 120 (84-132)                    | 0.054       |
| DR (%)                                 | 34 (39.1%)                          | 20 (58.8%)                         | 19 (52.8%)                          | 22 (71.0%)†                     | 0.013       |
| Cigarette smoking (%)                  | 40 (46.0%)                          | 19 (55.9%)                         | 18 (50.0%)                          | 16 (51.6%)                      | 0.790       |
| SBP (mmHg)                             | 144.26 ± 19.80                      | 149.91 ± 30.06                     | 148.86 ± 24.25                     | 153.71 ± 21.87                  | 0.224       |
| DBP (mmHg)                             | 86.01 ± 12.43                       | 84.59 ± 11.85                      | 84.60 ± 12.49                      | 89.32 ± 10.80                   | 0.354       |
| Hypertension (%)                       | 77 (88.5%)                          | 29 (85.3%)                         | 32 (88.9%)                          | 30 (96.8%)                      | 0.391       |
| Hematuria (%)                          | 39 (44.8%)                          | 24 (72.7%)†                        | 27 (79.4%)†                         | 22 (71.0%)                      | 0.001       |
| Initial proteinuria (g/d)              | 2.18 (0.93-3.66)                    | 5.02 (3.29-7.81)†                  | 5.55 (4.23-8.82)†                  | 8.4 (6.15-14.42)‡               | <0.001      |
| Nephrotic-range proteinuria (>3.5 g/d (%)) | 22 (25.3%)                          | 21 (63.6%)†                        | 30 (83.3%)†                         | 29 (93.5%)†                     | <0.001      |
| e-GFR (mL/min/1.73 m²)                 | 65.22 (40.88-91.11)                 | 52.14 (39.35-78.30)                | 42.16 (30.15-67.95)†               | 43.14 (28.92-59.22)‡            | <0.001      |
| Stage 1,2,3a,3b,4,5 CKD (KDIGO)        | 24/24/10/21/8/0                     | 5/8/10/6/5/0                       | 2/9/3/13/9/0                       | 0/7/7/9/8/0                     | —           |
| Serum creatinine (mg/dL)               | 1.21 (0.85-1.70)                    | 1.44 (1.07-1.67)                   | 1.62 (1.19-2.31)†                  | 1.80 (1.26-2.40)†               | 0.001       |
| Uric acid (mmol/L)                     | 413.60 ± 89.99                      | 369.54 ± 71.93†                   | 385.40 ± 67.20                     | 364.94 ± 74.24†                 | 0.006       |
| FBS (mmol/L)                           | 7.38 (5.86-9.10)                    | 7.23 (5.88-9.75)                   | 7.39 (4.74-10.22)                  | 5.73 (4.64-8.59)                | 0.451       |
| HbA1c (%)                              | 6.90 (6.10-8.40)                    | 7.55 (6.43-8.45)                   | 7.30 (6.30-8.70)                   | 6.80 (5.95-8.40)                | 0.706       |
| Triglyceride (mmol/L)                  | 1.83 (1.29-2.39)                    | 1.63 (1.21-2.32)                   | 1.63 (1.03-2.46)                   | 1.82 (1.26-2.59)                | 0.557       |
| Total cholesterol (mmol/L)             | 4.77 ± 1.20                         | 5.03 ± 1.18                       | 6.28 ± 1.82‡                       | 6.48 ± 2.03‡                    | <0.001      |
| Hemoglobin (g/L)                       | 129.45 ± 26.25                      | 116.91 ± 27.55                    | 107.46 ± 24.64†                    | 103.53 ± 19.16†                 | <0.001      |
| Progressed to ESRD (%)                 | 12 (13.8%)                          | 13 (38.2%)                         | 27 (75%)                           | 24 (77.4%)                      | —           |
| **Histopathological findings**         |                                     |                                    |                                      |                                  |             |
| **Glomerular class**                   |                                     |                                    |                                      | <0.001                          |             |
| I                                      | 10 (11.5%)                          | 0 (0)                              | 0 (0)                               | 0 (0)                           |             |
| IIa                                    | 29 (33.3%)                          | 1 (2.9)                            | 1 (2.8)                             | 3 (9.7)                         |             |
| IIb                                    | 8 (9.2)                             | 6 (17.6)                           | 5 (13.9)                            | 1 (3.2)                         |             |
| III                                    | 27 (31)                             | 20 (58.8)                          | 26 (72.2)                           | 22 (71)                         |             |
| IV                                     | 13 (14.9)                           | 7 (20.6)                           | 4 (11.1)                            | 5 (16.1)                        |             |
| IFTA                                   |                                     |                                    |                                      | 0.014                           |             |
| 0                                      | 5 (5.7)                             | 0 (0)                              | 1 (2.8)                             | 0 (0)                           |             |
| 1                                      | 49 (56.3)                           | 15 (44.1)                          | 14 (38.9)                           | 8 (25.8)                        |             |
| 2                                      | 24 (27.6)                           | 17 (50)                            | 20 (55.6)                           | 19 (61.3)                       |             |
| 3                                      | 9 (10.3)                            | 2 (5.9)                            | 1 (2.8)                             | 4 (12.9)                        |             |
| **Interstitial inflammation**           |                                     |                                    |                                      | 0.001                           |             |
| 0                                      | 10 (11.5)                           | 1 (2.9)                            | 1 (2.8)                             | 0 (0)                           |             |
| 1                                      | 70 (80.5)                           | 26 (76.5)                          | 21 (58.3)                           | 21 (67.7)                       |             |
| 2                                      | 7 (8)                               | 7 (20.6)                           | 14 (38.9)                           | 10 (32.3)                       |             |
| **Arteriolar hyalinosis**               |                                     |                                    |                                      | 0.006                           |             |
| 0                                      | 20 (23)                             | 0 (0)                              | 2 (5.6)                             | 4 (12.9)                        |             |
| 1                                      | 41 (47.1)                           | 14 (41.2)                          | 16 (44.4)                           | 15 (48.4)                       |             |
| 2                                      | 26 (29.9)                           | 20 (58.8)                          | 18 (50)                             | 12 (38.7)                       |             |
Table 1: Continued.

| Variables                      | Normal group ≥ 35 g/L (n = 87) | Mild group 30-35 g/L (n = 34) | Moderate group 25-30 g/L (n = 36) | Severe group < 25 g/L (n = 31) | p value |
|--------------------------------|---------------------------------|-------------------------------|----------------------------------|-------------------------------|--------|
| Therapy                        |                                 |                               |                                  |                                |        |
| RAAS inhibitor (%)             | 70 (80.5)                       | 28 (82.4)                     | 29 (80.6)                        | 25 (80.6)                     | 0.996  |
| Oral hypoglycemic agents (%)   | 45 (51.7)                       | 15 (44.1)                     | 5 (13.9)                        | 12 (38.7)                     | 0.002  |
| Insulin therapy (%)            | 59 (67.8)                       | 26 (76.5)                     | 29 (82.9)                        | 24 (77.4)                     | 0.330  |

16 months for the mild, moderate, and severe groups, respectively. As presented in Figure 2, the renal survival was significantly deteriorated by the degree of hypoalbuminemia (log-rank test, p < 0.001). The univariate Cox analysis demonstrated that the albumin level could significantly impact the renal outcome in these patients (hazard ratio (HR), per SD of serum albumin 0.35, 95% confidence interval (CI), 0.27-0.46, p < 0.001). Compared to the normal group (reference), the risk of renal failure increased by the albumin level: the HRs were 2.99 (95% CI, 1.36-6.61, p = 0.007) for the mild group, 6.03 (95% CI, 3.05-11.95, p < 0.001) for the moderate group, and 13.74 (95% CI, 6.63-28.44, p < 0.001) for the severe group. The adjusted HRs of albumin for renal outcomes are shown in Table 3. After adjusting for important clinical variables, renal pathological findings, and RAAS inhibitor use (model 3), lower levels of albumin remained independently associated with a higher risk of ESRD (HR, per SD of serum albumin 0.21, 95% CI, 0.06-0.67, p = 0.009). And the HRs were 2.09 (95% CI, 1.67-6.56, p = 0.205) for the mild group, 6.20 (95% CI, 1.95-19.76, p = 0.002) for the moderate group, and 7.37 (95% CI, 1.24-43.83, p = 0.028) for the severe group, compared with the reference. In model 3, the e-GFR was also an independent risk factor for renal prognosis in patients with DN (Supplementary Table 2).

In the multivariate model including the age, gender, e-GFR, and log (urinary protein) at baseline, addition of serum albumin as a categorical variable improved the AUC from 0.80 to 0.87. However, adding the serum albumin to the model did not improve the discrimination of the outcome (IDI = -0.16, 95% CI, (-0.21, -0.10)).

4. Discussion

In this study, we investigated the relationship between the serum albumin levels and clinicopathological features and renal outcomes in 188 patients with T2DM and biopsy-proven DN. The results showed that the albumin level had a significant inverse correlation with proteinuria, cholesterol, and histopathological damage, including glomerular lesions, IFTA, interstitial inflammation, and arteriolar hyalinosis, and a positive correlation with renal function and hemoglobin. Moreover, the severity of hypoalbuminemia was significantly associated with an adverse renal outcome, independent of clinical and histopathological features. Participants with the lowest level of albumin vs. the normal group demonstrated a 7.37-fold greater risk of ESRD. Thus, the results of this study suggested that low levels of serum albumin might have prognostic utility in DN. Our observations that patients with lower levels of serum albumin were more prone to progress to ESRD may alert nephrologists that such patients should be followed up closely and possibly given a more aggressive treatment.

A previous study from Japan also found that the serum albumin level was independently associated with proteinuria in Japanese DN patients [16], and another study examined the impact of hypoalbuminemia on the progression of kidney disease among 343 Caucasian (77%) and black patients with DN. They found that the hypoalbuminemia was significantly associated with an adverse renal outcome, independent of clinical and histopathological features. Participants with the lowest level of albumin vs. the normal group demonstrated a 2.5-fold greater risk of ESRD. However, the diagnosis of DN in their studies was based on the pathology but on clinical manifestations. Given that nondiabetic renal disease (NDRD) is common (27-82.9%) [10, 17, 18] among diabetic patients undergoing renal biopsy, the results in their studies might be less convincing. Thus, the findings in this study performed among patients with biopsy-based diagnosis of DN may be more justified.
Human serum albumin, as the most represented plasma protein, is synthesized in the liver and secreted into the vascular space to distribute in all body tissues [14]. It plays a decisive role in the maintenance of homeostasis and makes a balance between hydrostatic and colloid osmotic pressure within vessels [19]. Serum albumin also has many physiological functions, including binding many different substances, such as hormones, ions, and drugs [20], anti-inflammatory function, and antioxidant properties [21]. Growing evidence has proven that the hypoalbuminemia was caused by an inadequate energy or protein intake, impaired liver synthesis, decreased intestinal absorption, increased tissue catabolism, or increased loss [22] and is an important risk factor and predictor of increased morbidity/mortality despite of the implicated diseases [22]. In this study, the results strongly suggested that the serum levels of albumin related to the renal prognosis. Moreover, the serum albumin level had a significant inverse correlation with proteinuria and glomerular lesions, two well-known risk factors for DN progression, which might give some explanation for the association between the hypoalbuminemia and renal outcome. However, this was by no means the only possible cause.

Moshage et al. [23] reported that albumin was a negative acute-phase protein during inflammation, and the decrease in the albumin level was associated with the effect of IL-1, IL-6, and TNF-α on the hepatic synthesis. Zhang and Frei [24] found that normal concentrations of albumin could selectively inhibit TNF-α-induced expression of vascular cell adhesion molecule-1 (VCAM-1) to attenuate the inflammation. And the results of Michalis et al. [25–27] indicated that the modified/oxidized albumin molecules in diabetic patients have a key role in accelerating oxidative stress (OS), inflammation, and endothelial injury involving neutrophil activation due to possessing the proinflammatory properties. So, the level of serum albumin, to some extent, could reflect the degree of inflammation and OS. Taken all the above contributors together, it was possible that the chronic inflammatory state [28], reflected as hypoalbuminemia, accelerated the process of kidney function deterioration, possibly by inducing oxidative stress [25, 26, 29] and endothelial inflammatory injury [27]. That hypothesis has also been evidenced in both the nondiabetic [30, 31] and diabetic patients [32].

Generally, the patients with DN were often accompanied by a disorder of lipid metabolism. Unfortunately, in our study, the hypoalbuminemia was negatively correlated with the level of cholesterol, which in turn aggravated the dyslipidemia, causing a vicious circle that leads to more severe toxic injury to the kidney induced by the lipid. In addition, this study also found that the serum level of albumin positively correlated with the level of e-GFR and hemoglobin. The patients with a lower albumin level had a decreased renal function and hemoglobin level. Growing evidence suggested that impaired kidney function might lead to accumulation of inflammatory factors, which could, in return, aggravate kidney injury [33]. Moreover, the progression of DN could further bring about decreased protein and energy intake, and, consequently, malnutrition with a resultant more severe hypoalbuminemia [34]. Moreover, the patients with hypoalbuminemia were also prone to have anemia, which might result in an anemia-induced hypoxia that accelerates kidney injury in these patients [35]. Nevertheless, the exact underlying mechanism of the hypoalbuminemia associated with the kidney prognosis needs more clinical and experimental evidence to verify.

It is noteworthy that the results of this study indicated the prognostic impact of hypoalbuminemia; the subsequent question was how to improve the renal prognosis of these patients. Growing evidence suggested that the treatment with RAAs inhibitors was effective not only to reduce the level of albuminuria but also to maintain the level of serum albumin [36]. Moreover, several experimental and clinical studies reported that pentoxifylline can retard kidney disease progression and reduce the albuminuria level due to possessing the antioxidant, anti-inflammatory, and antifibrotic properties [37–40]. Beraprost sodium (BPS), a prostaglandin analogue, also had the capacity to improve renal function and decrease urinary protein excretion via reducing inflammatory cytokine production and oxidative stress, evidenced in DN rats [41]. However, whether the latent benefits of the anti-inflammatory and antiproteinuric effect, to some extent, relied on an increase in the serum albumin level was unknown in these setting. In addition, a low-protein diet (LPD) has been advised to improve uremic symptoms and slow the kidney disease progression in patients with CKD (including DN), which might be another cause for the hypoalbuminemia. Ketoanologs, which contained the essential amino acids, in conjunction with LPD treatment had been reported to delay the renal function decline, reduce albuminuria, and improve lipid metabolism without deteriorating the nutritional status—the underlying mechanism necessitating further research to clarify [42].
Some limitations in this study should be noted. First, it was a retrospective cohort study and selection bias was inevitable. Second, the association between serum albumin level changes and the renal prognosis should be cautiously regarded as correlation instead of causality. Third, the serum albumin levels were only analyzed at the baseline and the renal outcome was evaluated using an e-GFR. Fourth, oxidative modifications of serum albumin could also lead to "fictitious" hypoalbuminemia due to the underestimation of actual albumin levels using the BCG method in this study. Finally, we did not control the therapeutic interventions or dietary intake at baseline and during the follow-up.

5. Conclusions

In summary, our study found that the lower serum level of albumin was associated with the reduced kidney function and poor renal prognosis in patients with T2DM and DN, independent of clinical and histopathological features. Further, more clinical researches are warranted to verify whether the correction of hypoalbuminemia could improve renal prognosis in patients with DN.

Data Availability

The clinical and pathological data of all the DN patients used to support the findings of this study have not been made available to protect the patients' rights of privacy.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Acknowledgments

This study was supported by a Grant 81670662 from the National Natural Science Foundation of China.

### Table 3: Associations between serum albumin and renal outcomes.

| Serum albumin, median (range) (g/L) | Hazard ratios (95% confidence interval) & p value |
|------------------------------------|---------------------------------------------|
|                                    | Unadjusted | Model 1 | Model 2 | Model 3 |
| Per 1 SD serum albumin             |            |         |         |         |
| Normal group                       | 34.15 (14.00-48.80) | 0.35 (0.27-0.46) | 0.18 (0.06-0.58) | 0.20 (0.06-0.66) | 0.21 (0.06-0.67) | p < 0.001 | p = 0.004 | p = 0.008 | p = 0.009 |
| Mild group (35-30 g/L)             | 40.20 (35.10-48.80) | Reference | Reference | Reference | Reference |
| Moderate group (25-30 g/L)         | 33.25 (30.30-34.90) | 2.99 (1.36-6.61) | 1.45 (0.49-4.31) | 2.24 (0.72-6.90) | 2.09 (0.67-6.56) | p = 0.007 | p = 0.501 | p = 0.162 | p = 0.205 |
| Severe group (<25 g/L)            | 27.50 (25.20-29.90) | 6.03 (3.05-11.95) | 4.67 (1.59-13.74) | 6.56 (2.05-20.94) | 6.20 (1.95-19.76) | p < 0.001 | p = 0.005 | p = 0.001 | p = 0.002 |
| Normal group                      | 22.00 (14.00-24.80) | 13.74 (6.63-28.44) | 6.14 (1.27-29.66) | 10.61 (1.87-60.07) | 7.37 (1.24-43.83) | p < 0.001 | p = 0.024 | p = 0.008 | p = 0.028 |

Serum albumin was analyzed as a continuous variable with hazard ratios (HRs) calculated per SD increment. SD: standard deviation. *Model 1 adjusted for the baseline age, gender, duration of diabetes, DR (yes or no), hypertension (yes or no), hematuria, total cholesterol, hemoglobin, and log proteinuria and e-GFR. **Model 2 adjusted for covariates in model 1 plus renal pathological findings (the glomerular class, IFTA, interstitial inflammation scores, and arteriolar hyalinosis). ***Model 3 adjusted for covariates in model 2 plus RAAS inhibitor use (yes or no).

Supplementary Materials

Supplementary Table 1: the clinical features of the excluded and included patients in this study. Supplementary Table 2: Cox regression analysis of risk factors for renal outcomes in DN patients. (Supplementary Materials)

References

[1] R. Saran, B. Robinson, K. C. Abbott et al., "US Renal Data System 2016 Annual Data Report: epidemiology of kidney disease in the United States," *American Journal of Kidney Diseases*, vol. 69, no. 3, Supplement 1, pp. A7–A8, 2017.

[2] L. Zhang, J. Long, W. Jiang et al., "Trends in chronic kidney disease in China," *The New England Journal of Medicine*, vol. 375, no. 9, pp. 905-906, 2016.

[3] R. Z. Alicic, M. T. Rooney, and K. R. Tuttle, "Diabetic kidney disease: challenges, progress, and possibilities," *Clinical Journal of the American Society of Nephrology*, vol. 12, no. 12, pp. 2032–2045, 2017.

[4] G. L. Bakris, "Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus," *Mayo Clinic Proceedings*, vol. 86, no. 5, pp. 444–456, 2011.

[5] Z. H. Liu, "Nephropathy in China," *Nature Reviews Nephrology*, vol. 9, no. 9, pp. 523–528, 2013.

[6] R. Saran, Y. Li, B. Robinson et al., "US Renal Data System 2014 Annual Data Report: epidemiology of kidney disease in the United States," *American Journal of Kidney Diseases*, vol. 66, no. 1, Supplement 1, p. A7, 2015.

[7] E. W. Gregg, Y. Li, J. Wang et al., "Changes in diabetes-related complications in the United States, 1990–2010," *The New England Journal of Medicine*, vol. 370, no. 16, pp. 1514–1523, 2014.

[8] K. E. White and R. W. Bilous, "Type 2 diabetic patients with nephropathy show structural-functional relationships that are similar to type 1 disease," *Journal of the American Society of Nephrology*, vol. 11, no. 9, pp. 1667–1673, 2000.

[9] Y. An, F. Xu, W. Le et al., "Renal histologic changes and the outcome in patients with diabetic nephropathy," *Nephrology Dialysis Transplantation*, vol. 30, no. 2, pp. 257–266, 2015.
T. W. C. Tervaert, A. L. Mooyaart, K. Amann et al., “Renal pathological implications in type 2 diabetes mellitus patients with renal involvement,” *Journal of Diabetes and its Complications*, vol. 31, no. 1, pp. 114–121, 2017.

Y. H. Lee, K. P. Kim, Y. G. Kim et al., “Clinicopathological features of diabetic and nondiabetic renal diseases in type 2 diabetic patients with nephrotic-range proteinuria,” *Medicine*, vol. 96, no. 36, article e8047, 2017.

American Diabetes Association, “Standards of Medical Care in Diabetes—2017” abridged for primary care providers, *Clinical Diabetes*, vol. 35, no. 1, pp. 5–26, 2017.

T. W. C. Tervaert, A. L. Mooyaart, K. Amann et al., “Pathologic classification of diabetic nephropathy,” *Journal of the American Society of Nephrology*, vol. 21, no. 4, pp. 556–563, 2010.

A. Gatta, A. Verardo, and M. Bolognesi, “Hypoalbuminemia,” *Internal and Emergency Medicine*, vol. 7, Supplement 3, pp. 193–199, 2012.

K. Mise, J. Hoshino, T. Ueno et al., “Prognostic value of tubulointerstitial lesions, urinary N-acetyl-β-D-glucosaminidase, and urinary β2-microglobulin in patients with type 2 diabetes and biopsy-proven diabetic nephropathy,” *Clinical Journal of the American Society of Nephrology*, vol. 11, no. 4, pp. 593–601, 2016.

T. Iwasaki, Y. Tagoshi, and Y. Terauchi, “Significant association of serum albumin with severity of retinopathy and nephropathy, in addition to that of nephropathy, in Japanese type 2 diabetic patients,” *Endocrine Journal*, vol. 55, no. 2, pp. 311–316, 2008.

M. Fiorentino, D. Bolignano, V. Tesar et al., “Renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies,” *Nephrology Dialysis Transplantation*, vol. 32, no. 1, pp. 97–110, 2017.

S. W. Oh, S. Kim, K. Y. Na et al., “Clinical implications of pathologic diagnosis and classification for diabetic nephropathy,” *Diabetes Research and Clinical Practice*, vol. 97, no. 3, pp. 418–424, 2012.

J. P. Nicholson, M. R. Wolmarans, and G. R. Park, “The role of albumin in critical illness,” *British Journal of Anaesthesia*, vol. 85, no. 4, pp. 599–610, 2000.

G. Fanali, A. di Masi, V. Trezza, M. Marino, M. Fasano, and P. Ascenzi, “Human serum albumin: from bench to bedside,” *Molecular Aspects of Medicine*, vol. 35, no. 3, pp. 209–290, 2012.

S. Arques and P. Ambrosi, “Human serum albumin in the clinical syndrome of heart failure,” *Journal of Cardiac Failure*, vol. 17, no. 6, pp. 451–458, 2011.

G. Franch-Arcas, “The meaning of hypoalbuminemia in clinical practice,” *Clinical Nutrition*, vol. 20, no. 3, pp. 265–269, 2001.

H. J. Moshage, J. A. Janssen, J. H. Franssen, J. C. Hafkenscheid, and S. H. Yap, “Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation,” *The Journal of Clinical Investigation*, vol. 79, no. 6, pp. 1635–1641, 1987.

W. J. Zhang and B. Frei, “Albumin selectively inhibits TNFα-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells,” *Cardiovascular Research*, vol. 55, no. 4, pp. 820–829, 2002.

R. Michelis, B. Kristal, T. Zeitun et al., “Albumin oxidation leads to neutrophil activation in vitro and inaccurate measurement of serum albumin in patients with diabetic nephropathy,” *Free Radical Biology & Medicine*, vol. 60, pp. 49–55, 2013.

R. Michelis, B. Kristal, T. Snitkovsky, and S. Sela, “Oxidative modifications impair albumin quantification,” *Biochemical and Biophysical Research Communications*, vol. 401, no. 1, pp. 137–142, 2010.

F. Magzal, S. Sela, A. Szuclman-Sapir, S. Tamir, R. Michelis, and B. Kristal, “In-vivo oxidized albumin- a pro-inflammatory agent in hypoalbuminemia,” *PloS One*, vol. 12, no. 5, article e0177799, 2017.

J. T. and H. Makino, “Innate immunity in diabetes and diabetic nephropathy,” *Nature Reviews Nephrology*, vol. 12, no. 1, pp. 13–26, 2016.

S. B. Kim, W. S. Yang, and J. S. Park, “Role of hypoalbuminemia in the genesis of cardiovascular disease in dialysis patients,” *Peritoneal Dialysis International*, vol. 19, Supplement 2, pp. S144–S149, 1999.

E. M. Stuveling, H. L. Hillege, S. J. L. Bakker, R. O. B. Gans, P. E. de Jong, and D. de Zeeuw, “C-reactive protein is associated with renal function abnormalities in a non-diabetic population,” *Kidney International*, vol. 63, no. 2, pp. 654–661, 2003.

V. Menon, X. Wang, T. Greene et al., “Relationship between C-reactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease,” *American Journal of Kidney Diseases*, vol. 42, no. 1, pp. 44–52, 2003.

J. F. Navarro, C. Mora, M. Maciá, and J. García, “Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus,” *American Journal of Kidney Diseases*, vol. 42, no. 1, pp. 53–61, 2003.

B. J. G. Pereira, L. Shapiro, A. J. King, M. E. Falagas, J. A. Strom, and C. A. Dinarello, “Plasma levels of IL-1β, TNFα and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients,” *Kidney International*, vol. 45, no. 3, pp. 890–896, 1994.

D. J. Leehey, H. J. Kramer, T. M. Daoud, M. P. Chatha, and M. A. Isreb, “Progression of kidney disease in type 2 diabetes beyond blood pressure control: an observational study,” *BMC Nephrology*, vol. 6, no. 1, p. 8, 2005.

B. B. He, M. Xu, L. Wei et al., “Relationship between anemia and chronic complications in Chinese patients with type 2 diabetes mellitus,” *Archives of Iranian Medicine*, vol. 18, no. 5, pp. 277–283, 2015.

H. Yokoyama, O. Tomonaga, M. Hirayama et al., “Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients,” *Diabetologia*, vol. 40, no. 4, pp. 405–411, 1997.

M. E. Davila-Esqueda and F. Martinez-Morales, “Pentoxifylline diminishes the oxidative damage to renal tissue induced by streptozotocin in the rat,” *Experimental Diabetology Research*, vol. 5, no. 4, pp. 245–251, 2004.

J. F. Navarro, F. J. Milena, C. Mora, C. Leon, and J. García, “Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration,” *American Journal of Nephrology*, vol. 26, no. 6, pp. 562–570, 2006.

H. K. Sun, Y. M. Lee, K. H. Han, S. H. Kim, S. H. Ahn, and S. Y. Han, “Phosphodiesterase inhibitor improves renal tubulointerstitial hypoxia of the diabetic rat kidney,” *The Korean Journal of Internal Medicine*, vol. 27, no. 2, pp. 163–170, 2012.
[40] J. F. Navarro-González, C. Mora-Fernández, M. Muros de Fuentes et al., “Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial,” *Journal of the American Society of Nephrology*, vol. 26, no. 1, pp. 220–229, 2014.

[41] J. Guan, L. Long, Y. Q. Chen et al., “Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy,” *Genetics and Molecular Research*, vol. 13, no. 2, pp. 4154–4158, 2014.

[42] J. H. Chang, D. K. Kim, J. T. Park et al., “Influence of ketoanalog supplementation on the progression in chronic kidney disease patients who had training on low-protein diet,” *Nephrology*, vol. 14, no. 8, pp. 750–757, 2009.